(Q37130018)

English

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients (English)

1 reference

Europe PubMed Central

18 August 2017

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

Ronald van Vollenhoven

1

object named as

Ronald F van Vollenhoven

0 references

author name string

Clifton O Bingham

3

1 reference

Europe PubMed Central

18 August 2017

Edward C Keystone

4

1 reference

Europe PubMed Central

18 August 2017

Roy M Fleischmann

5

1 reference

Europe PubMed Central

18 August 2017

Daniel E Furst

6

1 reference

Europe PubMed Central

18 August 2017

Nicola Tyson

7

1 reference

Europe PubMed Central

18 August 2017

Neil Collinson

8

1 reference

Europe PubMed Central

18 August 2017

Patricia B Lehane

9

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

7 November 2012

1 reference

Europe PubMed Central

18 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

18 August 2017

72

1 reference

Europe PubMed Central

18 August 2017

9

1 reference

Europe PubMed Central

18 August 2017

1496-1502

1 reference

Europe PubMed Central

18 August 2017

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Cardiovascular morbidity and mortality in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Patterns of cardiovascular risk in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

14 September 2017

Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

29 September 2017

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

27 June 2018

Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

3 September 2018

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

3 September 2018

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

3 September 2018

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

3 September 2018

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

3 September 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

3 September 2018

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

3 September 2018

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

3 September 2018

All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3756452

3 September 2018

Rheumatoid arthritis and cancer risk

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-201956

21 January 2018

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-201956

21 January 2018

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23136242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23136242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23136242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/23136242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23136242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2012-201956

1 reference

Europe PubMed Central

18 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37130018&oldid=1688224658"